JP2019011344A5 - - Google Patents

Download PDF

Info

Publication number
JP2019011344A5
JP2019011344A5 JP2018176400A JP2018176400A JP2019011344A5 JP 2019011344 A5 JP2019011344 A5 JP 2019011344A5 JP 2018176400 A JP2018176400 A JP 2018176400A JP 2018176400 A JP2018176400 A JP 2018176400A JP 2019011344 A5 JP2019011344 A5 JP 2019011344A5
Authority
JP
Japan
Prior art keywords
virus
influenza
influenza virus
sia
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018176400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019011344A (ja
JP7260270B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019011344A publication Critical patent/JP2019011344A/ja
Publication of JP2019011344A5 publication Critical patent/JP2019011344A5/ja
Application granted granted Critical
Publication of JP7260270B2 publication Critical patent/JP7260270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018176400A 2006-09-11 2018-09-20 卵を使用しないインフルエンザウイルスワクチンの作製 Active JP7260270B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84372006P 2006-09-11 2006-09-11
US60/843,720 2006-09-11
US93627907P 2007-06-18 2007-06-18
US60/936,279 2007-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016021859A Division JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020028399A Division JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製

Publications (3)

Publication Number Publication Date
JP2019011344A JP2019011344A (ja) 2019-01-24
JP2019011344A5 true JP2019011344A5 (enExample) 2019-07-25
JP7260270B2 JP7260270B2 (ja) 2023-04-18

Family

ID=39184185

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2009527227A Active JP5954921B2 (ja) 2006-09-11 2007-09-11 卵を使用しないインフルエンザウイルスワクチンの作製
JP2016021859A Withdrawn JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製
JP2017038957A Pending JP2017101073A (ja) 2006-09-11 2017-03-02 卵を使用しないインフルエンザウイルスワクチンの作製
JP2018176400A Active JP7260270B2 (ja) 2006-09-11 2018-09-20 卵を使用しないインフルエンザウイルスワクチンの作製
JP2020028399A Withdrawn JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製
JP2021215388A Active JP7427648B2 (ja) 2006-09-11 2021-12-29 卵を使用しないインフルエンザウイルスワクチンの作製
JP2023074617A Pending JP2023093728A (ja) 2006-09-11 2023-04-28 卵を使用しないインフルエンザウイルスワクチンの作製

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009527227A Active JP5954921B2 (ja) 2006-09-11 2007-09-11 卵を使用しないインフルエンザウイルスワクチンの作製
JP2016021859A Withdrawn JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製
JP2017038957A Pending JP2017101073A (ja) 2006-09-11 2017-03-02 卵を使用しないインフルエンザウイルスワクチンの作製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020028399A Withdrawn JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製
JP2021215388A Active JP7427648B2 (ja) 2006-09-11 2021-12-29 卵を使用しないインフルエンザウイルスワクチンの作製
JP2023074617A Pending JP2023093728A (ja) 2006-09-11 2023-04-28 卵を使用しないインフルエンザウイルスワクチンの作製

Country Status (12)

Country Link
US (3) US20100010199A1 (enExample)
EP (4) EP2066345B1 (enExample)
JP (7) JP5954921B2 (enExample)
KR (1) KR20090057015A (enExample)
AU (1) AU2007297178B2 (enExample)
BR (1) BRPI0716536A2 (enExample)
CA (2) CA2663196A1 (enExample)
EA (1) EA200970271A1 (enExample)
ES (3) ES2536401T3 (enExample)
MX (1) MX2009002408A (enExample)
NZ (1) NZ575271A (enExample)
WO (1) WO2008032219A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567981A (en) * 2005-11-04 2011-10-28 Novartis Vaccines & Diagnostic Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2007330494B2 (en) * 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
CA2741961A1 (en) * 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
SI2396030T1 (sl) * 2009-02-10 2015-12-31 Novartis Ag Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
CA2752041A1 (en) * 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
USH2284H1 (en) * 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
JP5823379B2 (ja) 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
CN101804203A (zh) * 2010-05-10 2010-08-18 洛阳普莱柯生物工程有限公司 一种大规模生产伪狂犬病毒疫苗的方法
ES2531577T3 (es) * 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
WO2012033236A1 (ko) 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
ES2572391T3 (es) 2011-02-25 2016-05-31 Novartis Ag Control exógeno interno positivo para la detección de virus
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CN102586195B (zh) * 2011-12-01 2013-09-04 哈药集团生物疫苗有限公司 一种利用Vero传代细胞制备禽流感病毒及其灭活疫苗的方法
WO2013088367A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
WO2016118937A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
KR102453351B1 (ko) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110237246B (zh) * 2019-07-25 2022-11-15 北京鼎持生物技术有限公司 一种全悬浮细胞培养禽流感（h9）灭活疫苗的方法
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
CN120888511B (zh) * 2025-09-28 2025-12-23 成都欧林生物科技股份有限公司 一种qmc流感毒种及其制备方法和应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988430A (en) * 1975-02-10 1976-10-26 Hoffmann-La Roche Inc. Immunoassay of antipyrine
US4315906A (en) * 1979-05-21 1982-02-16 New England Nuclear Corporation Cold insoluble globulin, its purification and use
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8703696D0 (en) 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
SG70625A1 (en) 1991-03-01 2000-02-22 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
AU681687B2 (en) 1993-07-15 1997-09-04 Minnesota Mining And Manufacturing Company Imidazo(4,5-c)pyridin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6630161B1 (en) 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
IL142395A0 (en) 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
DK1150918T3 (da) 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
ATE272410T1 (de) 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
WO2000060050A2 (en) 1999-04-06 2000-10-12 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ATE353370T1 (de) 1999-07-14 2007-02-15 Sinai School Medicine In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
CA2383105C (en) 1999-09-24 2010-01-26 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
MXPA02003068A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Adyuvante que comprende un eter o ester alquilo de polioxietileno y al menos un tensioactivo no ionico..
MXPA02003067A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Uso de combinacion de ester sorbitano de polioxietileno y octoxinol como adjuvante y su uso en vacunas.
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AU3604201A (en) 2000-03-03 2001-09-12 Chemo Sero Therapeut Res Inst Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
DK1317559T3 (da) 2000-04-28 2009-03-23 St Jude Childrens Res Hospital DNA-transfektionssystem til frembringelse af smitsom negativstrenget RNA-virus
PT1313734E (pt) 2000-09-01 2010-02-09 Novartis Vaccines & Diagnostic Derivados aza heterocíclicos e sua utilização terapêutica
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
CA2438960A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
US7524509B2 (en) 2001-03-09 2009-04-28 Id Biomedical Corporation Of Quebec Proteosome-liposaccharide vaccine adjuvant
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
KR100938590B1 (ko) * 2001-07-02 2010-01-26 아임스코 리미티드 폴리클론항체 항-ｈｉｖ 산양 혈청의 치료제로의 용도
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
HRP20040541A2 (en) 2001-11-27 2004-10-31 Anadys Pharmaceuticals 3- -D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
DE60329910D1 (de) 2002-03-29 2009-12-17 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
JP2005531599A (ja) 2002-05-29 2005-10-20 スリーエム イノベイティブ プロパティズ カンパニー イミダゾ［４，５−ｃ］ピリジン−４−アミンのための方法
US7250443B2 (en) 2002-08-23 2007-07-31 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
CA2511646A1 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1722815A1 (en) * 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
DK1742659T3 (da) 2004-04-05 2013-06-03 Zoetis P Llc Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
US20080254067A1 (en) 2004-05-20 2008-10-16 Id Biomedical Corporation Process for the Production of an Influenza Vaccine
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
SI1789084T1 (sl) * 2004-09-09 2011-03-31 Novartis Vaccines & Diagnostic Zmanjševanje potencialnih iatrogenih tveganj, povezanih z influenčnimi cepivi
AU2005322353B2 (en) 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
RU2435855C2 (ru) 2004-12-24 2011-12-10 Солвей Байолоджикалз Б.В. Способ продуцирования репликативной частицы вируса гриппа, композиция клеток (варианты), композиция клеточной культуры и ее применение
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
JP5602366B2 (ja) 2005-11-01 2014-10-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン

Similar Documents

Publication Publication Date Title
JP2019011344A5 (enExample)
US7037707B2 (en) Method for generating influenza viruses and vaccines
CA2468957C (en) Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
WO2007132763A1 (ja) インフルエンザウイルスの増殖方法
JP2015119730A5 (enExample)
WO2001064846A1 (fr) Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
JP2016509864A5 (enExample)
RU2708151C2 (ru) Плазмиды и способ получения вирусных частиц
Shin et al. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines
CN110520525B (zh) 流感工作病毒种苗与制备、增加其感染力及制备疫苗方法
EP2716752A1 (en) Canine influenza recombinant virus, preparation method therefor and application thereof
CN103118704B (zh) 经修饰的病毒株及用于改善流感病毒的疫苗种子的产生的方法
US20140377308A1 (en) METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES
WO2020004425A1 (ja) インフルエンザウイルスの培養方法
WO2020166524A1 (ja) 増殖方法
US20040142450A1 (en) Lung epithelial cell line for propagating viruses
CN1644686B (zh) 流感病毒哺乳动物细胞高产毒株、其重组毒株及其制备方法和应用
Mehrbod et al. Comparison of Vero and MDCK cell lines transfected with human siat7e gene for conversion to suspension culture
CN102234637A (zh) 重组甲型h1n1流感病毒灭活疫苗株(sc/pr8)的制备及应用
CN104178457A (zh) 稳定共表达人源Siat7e和ST3GalIV的MDCK细胞系及用途
JP6748067B2 (ja) インフルエンザウイルス作出用細胞
Liu et al. Screening of a high growth influenza B virus strain in Vero cells
Elderfield et al. Using reverse genetics to improve influenza vaccines
Suzuki Recent research on influenza virus receptor and the mechanism of its host range mutation
van Wielink et al. Effect of natural and chimeric haemagglutinin genes on influenza A virus replication in baby hamster kidney cells